COVID-19 Testing

Aegis COVID-19 Testing

9/2/20 - Aegis Sciences Corporation announces it has been awarded $6.6 million NIH grant to rapidly expand COVID-19 test capacity.  Capacity for 60,000 tests a day expected by September 30 with most results available within 24 hours.  Read full press release.

8/31/20 - Aegis Sciences Corporation Announces National Launch of COVID-19 Antibody Testing Utilizing Convenient Dry Blood Spot Technology.  Capacity for 10,000 tests a day;  Results available within 24 hours. Click here to read the press release.

08/28/20 - Note to Health Plans, Patients, and Governmental Entities—Pricing and Coding for the Aegis COVID-19 Antibody Test (#05701 - SARS-CoV-2, Antibody, IgG)—Effective August 28, 2020

  • Pricing:      Aegis will accept reimbursement of $42.13 per test for SARS-CoV-2, Antibody, IgG (test #05701)
  • Coding:      86769

8/13/20 - HHS Announces collaboration with Aegis Sciences Corporation to ramp high quality COVID-19 RT-PCR testing with fast results.  Click the link for more information  https://www.hhs.gov/about/news/2020/08/13/hhs-invests-in-diagnostic-labs-to-expand-covid-19-testing-capacity-in-the-united-states.html

  • For inquiries concerning Aegis’s collaboration with HHS, and/or testing for federal, state, and local governmental entities, please contact Joel Galanter, Chief Legal Officer (615-577-4509), joel.galanter@aegislabs.com
  • For inquiries concerning COVID-19 testing needs for clinical entities, universities/schools, employers etc., please contact Mike Ziegler, Chief Sales Officer (803-431-6178), mike.ziegler@aegislabs.com or Regina Sweeney, Vice President Client Relations (615-308-6302), regina.sweeney@aegislabs.com

05/08/2020 - Aegis Sciences Corporation now offering COVID-19 Employee Testing Program - Click here for more information.
Please contact Mike Ziegler, Chief Sales Officer for inquiries.

04/27/2020 - Aegis Sciences Corporation Doubles Capacity for Coronavirus Disease 2019 (COVID-19) Testing. Capacity for 7,000 tests a day begins May 4 in response to community need. Read full press release

04/13/2020 - Aegis launches test for Coronavirus disease 2019 (COVID-19). Our dedicated team of lab scientists has worked diligently to leverage Aegis’s strong lab capabilities and moved quickly to offer this valuable diagnostic tool to aid in the fight against COVID-19. Capacity for 3,500 tests a day beginning April 15, 2020; results available within 24 hours. Read full press release

04/15/20 - Notice to Health Plans, Patients, and Governmental Entities –Pricing and Coding for Aegis COVID-19 (SARS-CoV-2, qPCR) Testing – Effective 04/15/2020 

  • Pricing:         $100 per test (same for all CPT codes)
  • Coding:         U0003

On April 14th, Centers for Medicare and Medicaid Services (CMS) announced new procedure codes and associated pricing for COVID-19 testing performed utilizing high-throughput technologies capable of processing large volumes of COVID-19 tests rapidly. CMS took this action in light of the high cost of resources, required investment, and advanced technical requirements associated with utilizing high-throughput technologies. All of Aegis’s COVID-19 tests are performed utilizing advanced high-throughput platforms. Aegis will continue to align with the floor pricing established by CMS, which is $100 for Aegis’s test, and accept that amount as payment for its COVID-19 testing.


04/16/2020
 - Aegis Sciences gears up for COVID-19 testing.  Featured on WSMV News4 Nashville View Clip

 

  • Downstream effects of COVID-19 on your patients

    Downstream effects of COVID-19 on your patients

    Date and Time:

    Length: 30 minutes

Resources

  1. Patient Portal

    If you are a patient that had COVID-19 testing performed by Aegis Sciences click below to retrieve your results:

    https://Patientportal.aegislabs.com

  2. COVID-19 Testing FAQs

     

    Aegis’ COVID-19 testing FAQ provides information specific to our lab’s testing capabilities.  Additionally, the FAQ document summarizes pertinent information from various resources leading the fight against the COVID-19 pandemic.

    Clinical FAQ for COVID-19 Diagnostic Testing

    Clinical FAQ for COVID-19 Antibody Testing

  3. Specimen Collection Instructions
  4. COVID-19 Fact Sheets

    Aegis' COVID-19 Fact Sheets provides information for patients and providers regarding the risks and benefits of using Aegis' tests for COVID-19. For both providers and patients, the test used can be found in the "Sample Comments" section of the Laboratory Report.

    Patient Fact Sheet

    Patient Fact Sheet

    This Fact Sheet contains information to help you understand the risks and benefits of using this test for the diagnosis of COVID-19. After reading this Fact Sheet, if you have questions or would like to discuss the information provided, please talk to your healthcare provider. 

    Taq-Path™ COVID-19 Combo Kit : Download Patient Fact Sheet (English - Taq-Path)

    SARS-CoV-2 qPCR - Aegis Sciences Corporation : Download Patient Fact Sheet (English - Aegis Sciences Corporation)

    SARS-CoV-2 qPCR - Aegis Sciences Corporation : Download Patient Fact Sheet (Spanish - Aegis Sciences Corporation)

     

  5. Antibody Patient Fact Sheet

    Antibody Patient Fact Sheet

    This Fact Sheet contains information pertaining to testing for antibodies to the virus that causes Coronavirus Disease 2019 (COVID-19) using a SARS-CoV-2 Antibody Test that was authorized for emergency use by FDA.  After reading this Fact Sheet, if you have questions or would like to discuss the information provided, please talk to your healthcare provider.  

    Download Patient Fact Sheet – English

     

  6. This Fact Sheet informs you of the significant known and potential risks and benefits of the emergency use of the TaqPath™ COVID-19 Combo Kit.

    Provider Fact Sheet

    Provider Fact Sheet

    This Fact Sheet informs you of the significant known and potential risks and benefits of the emergency use of a Molecular Laboratory Developed Test (LDT) COVID-19 Authorized Test (Molecular LDT COVID-19 Authorized Test) that has been issued an Emergency Use Authorization (EUA) by FDA. The Molecular LDT COVID-19 Authorized Test is authorized for use on respiratory specimens collected from individuals suspected of COVID-19 by their healthcare provider. 

    Taq-Path™COVID-19 Combo Kit : Download Provider Fact Sheet (English - Taq-Path)

    SARS-CoV-2 qPCR - Aegis Sciences Corporation : Download Provider Fact Sheet (English - Aegis Sciences Corporation)

  7. Antibody Provider Fact Sheet

    Antibody Provider Fact Sheet

    This Fact Sheet informs you of the significant known and potential risks and benefits of the emergency use of certain SARS-CoV-2 Antibody Tests.

    Download Provider Fact Sheet